特點(diǎn) Feature | 說明 Description | 客戶價值 Value |
First-in-Class Non-Opioid Analgesic 首創(chuàng)非阿片類鎮(zhèn)痛藥 | First FDA-approved intrathecal analgesic that works through a non-opioid mechanism by selectively blocking N-type calcium channels (Cav2.2) in the spinal cord. 首個FDA批準(zhǔn)的通過非阿片類機(jī)制發(fā)揮作用的鞘內(nèi)鎮(zhèn)痛藥，選擇性阻斷脊髓中N型鈣通道（Cav2.2）。 | No risk of respiratory depression, opioid-induced hyperalgesia, tolerance development, or addiction - addressing critical unmet needs in chronic pain management. 無呼吸抑制、阿片誘導(dǎo)痛覺過敏、耐受性或成癮風(fēng)險 - 滿足慢性疼痛管理中的關(guān)鍵未滿足需求。 |
Potent & Selective Action 強(qiáng)效選擇性作用 | Three disulfide bridges stabilize the conformation for high-affinity binding to Cav2.2 channels, providing potent analgesia at nanomolar concentrations. 三個二硫鍵穩(wěn)定構(gòu)象，以高親和力結(jié)合Cav2.2通道，在納摩爾濃度下提供強(qiáng)效鎮(zhèn)痛。 | Superior pain relief for patients with neuropathic pain, cancer pain, and opioid-refractory conditions. 對神經(jīng)病理性疼痛、癌痛和阿片類藥物難治性病癥患者的疼痛緩解效果優(yōu)異。 |
No CNS Side Effects 無中樞副作用 | Intrathecal delivery bypasses systemic circulation, minimizing central nervous system and systemic adverse effects common with oral/systemic analgesics. 鞘內(nèi)給藥繞過全身循環(huán)，最大限度地減少口服/全身鎮(zhèn)痛藥常見的中樞神經(jīng)系統(tǒng)和全身不良反應(yīng)。 | Improved patient quality of life and compliance compared to systemic opioid therapy with equivalent or superior efficacy. 與全身阿片類藥物治療相比，療效相當(dāng)或更優(yōu)，患者生活質(zhì)量和依從性得到改善。 |
Complex Peptide Manufacturing 復(fù)雜肽合成能力 | 25-amino acid peptide with three critical disulfide bridges requires advanced synthetic expertise; supplied at >=98.0% purity with full analytical documentation. 含三個關(guān)鍵二硫鍵的25氨基酸肽需要先進(jìn)合成技術(shù)；提供>=98.0%純度及完整分析文件。 | Access to a rare and technically challenging API backed by validated synthesis and quality control processes. 獲得稀有且技術(shù)要求高的API，以經(jīng)過驗(yàn)證的合成和質(zhì)量控制流程為后盾。 |
Complete Regulatory Package 完整法規(guī)包 | Comprehensive CMC documentation including detailed synthetic route, impurity profile, and stability data for global registration support. 全面的CMC文件，包括詳細(xì)合成路線、雜質(zhì)譜和穩(wěn)定性數(shù)據(jù)，支持全球注冊。 | Accelerated market entry for generic developers and formulation partners targeting chronic pain therapeutics. 加速仿制藥開發(fā)商和制劑合作伙伴進(jìn)入慢性疼痛治療市場。 |
Scalable Supply 可擴(kuò)展供應(yīng) | Production capacity from gram-scale for R&D to kilogram-scale for commercial supply, with consistent batch-to-batch quality. 從克級研發(fā)到公斤級商業(yè)供應(yīng)的生產(chǎn)能力，批次間質(zhì)量一致。 | Supports seamless transition from clinical trials to commercial launch with reliable supply chain planning. 支持從臨床試驗(yàn)到商業(yè)上市的平穩(wěn)過渡，供應(yīng)鏈規(guī)劃可靠。 |
End-to-End Procurement 端到端采購 | Single-source supply of API, reference standards, stability-indicating methods, and regulatory submission packages. API、對照品、穩(wěn)定性指示方法和法規(guī)申報包的單一來源供應(yīng)。 | Reduces procurement complexity and ensures full traceability from synthesis to final delivery. 降低采購復(fù)雜性，確保從合成到最終交付的完整可追溯性。 |